Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Cardio Diagnostics Holdings's average Book Value per Share Growth Rate was -55.10% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -34.50% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 56.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 6 years, the highest 3-Year average Book Value per Share Growth Rate of Cardio Diagnostics Holdings was 183.80% per year. The lowest was -34.50% per year. And the median was 22.80% per year.
Cardio Diagnostics Holdings (NAS:CDIO) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Cardio Diagnostics Holdings 3-Year Book Growth Rate Related Terms
CDIO vs ERNA, LABT, JAGX: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Cardio Diagnostics Holdings's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardio Diagnostics Holdings 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Cardio Diagnostics Holdings's 3-Year Book Growth Rate falls into.
Cardio Diagnostics Holdings 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -34.50% mean?
Cardio Diagnostics Holdings (CDIO) has a 3-Year Book Growth Rate of -34.50% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Cardio Diagnostics Holdings and its competitors. According to the industry distribution chart, Cardio Diagnostics Holdings ranks #861 out of 1131 companies in the Biotechnology industry, placing it in the top 76.1%.
Is Cardio Diagnostics Holdings' 3-Year Book Growth Rate too high?
Cardio Diagnostics Holdings' current 3-Year Book Growth Rate is -34.50%. Based on the distribution chart, Cardio Diagnostics Holdings ranks #861 out of 1131 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardio Diagnostics Holdings has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' 3-Year Book Growth Rate compare to ERNA and LABT?
According to the Biotechnology industry distribution chart, Cardio Diagnostics Holdings ranks #861 out of 1131 companies for 3-Year Book Growth Rate. This places Cardio Diagnostics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Cardio Diagnostics Holdings and its competitors. Cardio Diagnostics Holdings's current 3-Year Book Growth Rate is -34.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.80, compared to a current price of $2.02 — trading 12.4% above its estimated fair value. The current 3-Year Book Growth Rate is -34.50%. Cardio Diagnostics Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current 3-Year Book Growth Rate is -34.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be overvalued.
The current stock price of $2.02 is trading 12.4% above its estimated GF Value™ of $1.80.
GuruFocus considers Cardio Diagnostics Holdings to be Modestly Overvalued.
Key valuation signals for CDIO:
3-Year Book Growth Rate: -34.50%
GF Value™: $1.80 vs. price of $2.02 (12.4% above fair value)
No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
53GF Score
Get the complete analysis for CDIO
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIO has been successfully added to your 
